Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence and Food Effect of ASC-01 (Aripiprazole/Sertraline) in Healthy Males
NCT03342963Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Nov 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of aripiprazole + sertraline in major depressive disorder (MDD) (4 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoints: Peak Plasma Concentration at 168 hours and Area Under the Plasma Concentration Versus Time Curve 168h. Started Nov 2017; status: completed.
02
Drugs
aripiprazole + sertraline
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03342963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03342963.